Results 71 to 80 of about 125,582 (281)

Future directions for the management of pain in osteoarthritis.

open access: yes, 2014
Osteoarthritis (OA) is the predominant form of arthritis worldwide, resulting in a high degree of functional impairment and reduced quality of life owing to chronic pain. To date, there are no treatments that are known to modify disease progression of OA
Kuttapitiya, A, Sofat, N
core   +1 more source

Histidine Supplementation Stabilizes Hearing and Vision and Improves Growth in HARS1‐Related Autosomal Recessive Disorder Associated With Usher‐Like Symptoms

open access: yesAmerican Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Autosomal recessive HARS1‐related disorder (originally described as Usher syndrome type 3B) caused by a homozygous Y454S variant in the histidyl‐tRNA synthetase gene (HARS1) is characterized by progressive sensorineural hearing and vision loss and respiratory deterioration with risk for sudden death following febrile illnesses.
Victoria Mok Siu   +23 more
wiley   +1 more source

The Impact of Differential Cost Sharing of Non-Steroidal Anti-Inflammatory Agents on the Use and Costs of Analgesic Drugs [PDF]

open access: yes
OBJECTIVE: To estimate the effect of differential cost sharing (DCS) schemes for non-steroidal anti-inflammatory drugs (NSAIDs) on drug subsidy program and beneficiary expenditures.
Bernie J. O'Brien   +5 more
core  

NSAIDs and gastrointestinal cancer prevention

open access: yes, 2002
Numerous studies report the relationship between aspirin and other nonsteroidal anti-inflammatories (NSAIDs) and cancer incidence, in particular for colorectal cancer.
Jolly, Catherine; id_orcid   +2 more
core   +1 more source

Inflammation Unchecked: Concurrent Kawasaki Disease and Stevens‐Johnson Syndrome in an 18‐Month‐Old Child

open access: yes
Arthritis Care &Research, EarlyView.
Catherine Deffendall   +6 more
wiley   +1 more source

Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent, often Type 2‐mediated inflammatory disease that markedly impairs quality of life. While dupilumab provides rapid improvement, there is limited evidence on long‐term outcomes beyond 2 years, and the clinical impact of dosing‐interval extension remains unclear.
Nicholas J. Campion   +15 more
wiley   +1 more source

Diverticulitis—new evidence to share with patients [PDF]

open access: yesExploration of Digestive Diseases
Diverticulitis is one of the most common gastrointestinal causes of hospitalization in Western society. While previously characterized as a disease of older patients, new literature highlights an increasing incidence among the younger population.
Nicholas B. D’Alessandro   +3 more
doaj   +1 more source

รูปแบบและความสมเหตุผลการสั่งใช้ยากลุ่ม NSAIDs ในผู้ป่วยนอกที่เป็นโรคข้อเสื่อม ของโรงพยาบาลทั่วไปแห่งหนึ่ง Pattern and Rationality of NSAIDs Prescribing in Out-patients with Osteoarthritis of a Tertiary-care Hospital

open access: yes, 2023
บทคัดย่อ วัตถุประสงค์: เพื่อศึกษารูปแบบและความสมเหตุผลของการสั่งใช้ยาแก้อักเสบที่ไม่ใช่สเตียรอยด์ (non-steroidal anti-inflammatory drugs; NSAIDs) ในผู้ป่วยนอกที่เป็นโรคข้อเสื่อมของโรงพยาบาลทั่วไปแห่งหนึ่ง วิธีการศึกษา: ศึกษาข้อมูลใบสั่งยาย้อนหลังตั้งแต ...
wongsuwon, sujitta   +1 more
core  

Extent of Sinus Surgery Is Associated With Disease Control in Biologic Treated Type 2 Dominant CRS

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background A greater benefit of biologics is observed after surgery in Type 2 chronic rhinosinusitis with nasal polyps (CRSwNP). However, the extent of surgery remains undefined in many studies. This study evaluated the extent of surgery on disease control in patients receiving biologics for refractory Type 2 dominant CRSwNP.
Nicholas J. Campion   +11 more
wiley   +1 more source

STUDY OF THE ANALGESIC AND ANTI-INFLAMMATORY ACTIVITY OF A NEW NON-OPIOID ANALGESIC BASED ON A SELECTIVE INHIBITOR OF TRPA1 ION CHANNELS

open access: yesКубанский научный медицинский вестник, 2019
The aim is to study the analgesic and anti-inflammatory activity of an innovative molecule under the ZC02-0012 laboratory code belonging to the group of selective blockers of the TRPA1 ion channel.Materials and methods.
Evgeniya A. Beskhmelnitsyna   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy